A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.

PHASE2CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

June 13, 2022

Primary Completion Date

October 5, 2022

Study Completion Date

October 5, 2022

Conditions
Postsurgical Pain Management
Interventions
DRUG

HR18034

HR18034 low dose

DRUG

HR18034

HR18034 midium dose

DRUG

HR18034

HR18034 high dose

DRUG

ropivacaine HCl.

ropivacaine HCl.

Trial Locations (18)

100005

Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing

110000

General Hospital of Northern Theater Command, Shenyang

116001

Affiliated Zhongshan Hospital of Dalian University, Dalian

225300

Taizhou People's Hospital, Taizhou

230000

The Second Affiliated Hospital of Anhui Medical University, Hefei

250000

Central Hospital Affiliated to Shandong First Medical University, Jinan

314000

Jiaxing Second Hospital, Jiaxing

315040

Li Huili Hospital of Ningbo Medical Center, Ningbo

410000

The Third Xiangya Hospital of Central South University, Changsha

415000

the first People's Hospital of Changde, Changde

442099

Shiyan Taihe Hospital, Shiyan

523000

Dongguan people's Hospital, Dongguan

530000

Nanning Second People's Hospital, Nanning

550000

The Affiliated Hospital of Guizhou Medical University, Guiyang

610072

Sichuan Provincial People's Hospital, Chengdu

710061

the First Affiliated Hospital of Xi'An Jiaotong University, Xi’an

710077

The First Affiliated Hospital of Xi'an Medical University, Xi’an

050000

Traditional Chinese Medicine Hospital of Hebei Province, Shijiazhuang

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY